This move is archived. Current quotes and coverage live on the stock page.
Get FRX alerts:
Fennec Pharmaceuticals Inc is making waves on the TSX with a notable gain of 2.34% in the last trading session, closing at CA$12.69.
In a market often characterized by volatility, Fennec Pharmaceuticals Inc (FRX.TO) stands out with a solid performance, reflecting investor confidence in its growth trajectory. The stock's recent rise can be attributed to positive developments surrounding its lead product, PEDMARK®, and its expanding market presence.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$599.65M
52W high
$17.64
52W low
$7.59
1W change
-1.10%
Beta
1.10
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 447.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+447.2% Upside
Current Price
C$17.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
67.7%
Annualized
90-Day Vol
76.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$20.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$18.15 | C$14.37 – C$22.92 |
| 60 trading days | C$19.26 | C$13.85 – C$26.80 |
| 90 trading days | C$20.44 | C$13.64 – C$30.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Fennec Pharmaceuticals as it navigates significant clinical advancements and market opportunities, potentially leading to sustained growth.
Fennec Pharmaceuticals Inc Gains 2.34% in One Day
The stock closed at CA$12.69, reflecting a growing confidence among investors amidst recent clinical advancements.
Bull case
The company recently reported a 73% year-over-year increase in net revenues, showing strong demand for its products. The acceptance of multiple abstracts at the prestigious ASCO Annual Meeting highlights increasing clinical interest in its offerings, which could strengthen its market position.
Bear case
Despite the positive momentum, Fennec Pharmaceuticals operates in a highly competitive sector with inherent risks. The company's lack of profitability and ongoing litigation related to its patents may pose challenges that investors need to consider.
Recent Performance Highlights
Advertisement
Fennec Pharmaceuticals Inc has shown a remarkable performance with a 2.34% increase in its stock price in the last trading session, closing at CA$12.69. This rise reflects positive investor sentiment driven by the company's recent financial results and ongoing clinical studies.
Key Developments Driving Growth
The company's first-quarter 2026 financial results revealed a significant 73% increase in net revenues, thanks to its expanding field sales efforts. Furthermore, the acceptance of multiple abstracts for the upcoming ASCO Annual Meeting underscores the rising clinical interest in its treatment for cisplatin-induced hearing loss.
Market Outlook
While the recent gains are encouraging, investors should remain cautious. Fennec Pharmaceuticals faces challenges typical of the pharmaceutical industry, including competition and the need for continued innovation. Monitoring future clinical outcomes and market responses will be crucial for assessing the stock's long-term viability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
